Amy Simon
Known title: Chief Medical OfficerCIK: 0001963879
Associated companies
Transaction History
| BEAM | ▼ Sell | Open Market | 16,667 | $429K | 7/27/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 373 | $13K | 6/30/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 6,700 | $165K | 4/1/2026 | View on chart |
| BEAM | ▲ Buy | Grant | 31,750 | $0 | 3/31/2026 | View on chart |
| BEAM | ▲ Buy | Grant | 12,500 | $0 | 12/31/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 876 | $18K | 7/3/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 374 | $6K | 7/1/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 20,997 | $372K | 4/2/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 9,566 | $176K | 4/1/2025 | View on chart |
| BEAM | ▲ Buy | Grant | 27,500 | $0 | 3/31/2025 | View on chart |
| BEAM | ▼ Sell | Open Market | 748 | $17K | 7/2/2024 | View on chart |
| BEAM | ▼ Sell | Open Market | 502 | $12K | 7/1/2024 | View on chart |
| BEAM | ▼ Sell | Open Market | 16,530 | $505K | 4/2/2024 | View on chart |
| BEAM | ▼ Sell | Open Market | 7,157 | $230K | 4/1/2024 | View on chart |
| BEAM | ▲ Buy | Grant | 27,500 | $0 | 3/31/2024 | View on chart |
| BEAM | ▼ Sell | Open Market | 3,448 | $64K | 10/30/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 391 | $12K | 7/10/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 10,493 | $312K | 4/4/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 1,161 | $34K | 4/4/2023 | View on chart |
| BEAM | ▼ Sell | Open Market | 4,445 | $135K | 4/3/2023 | View on chart |
| BEAM | ▲ Buy | Grant | 20,000 | $0 | 3/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Beam Therapeutics to present BEAM-301 data at ESGCT congress
Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.
Beam Therapeutics to present BEAM-301 data at ESGCT congress. Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.